Novel Intravaginal Drug Delivery System Based on Molecularly PEGylated Lipid Matrices for Improved Antifungal Activity of Miconazole Nitrate

Table 4

Some physicochemical and anticandidal properties of MN-loaded SLMs.

Batch code	Yield; (%)	Encapsulation efficiency; (%)	Loading capacity; (g API/100 g lipid)	Inhibition zone diameter; (mm±SD)
A0	97.90	-	-	-
AM1	97.58	54.01	5.40	24.00 ± 0.00
AM2	98.22	77.38	15.47	24.67 ± 0.47
AM3	98.40	87.75	26.33	25.87 ± 0.94
B0	98.92	-	-	-
BM1	99.02	73.61	25.99	24.00 ± 0.00
BM2	96.54	81.42	16.28	25.00 ± 0.00
BM3	97.90	86.64	7.36	26.00 ± 0.00
C0	97.44	-	-	-
CM1	94.76	81.42	8.14	24.33 ± 0.47
CM2	98.10	82.26	16.45	25.67 ± 0.47
CM3	99.52	83.05	24.92	26.33 ± 0.47
D0	98.26	-	-	-
DM1	96.52	47.55	4.76	24.33 ± 0.47
DM2	97.80	64.11	12.82	25.83 ± 0.94
DM3	97.66	83.33	25.00	26.33 ± 0.94

Keys: A₀, AM₁, AM₂, and AM₃ are non-PEGylated SLMs; batches B–D are PEGylated SLMs containing increasing concentrations (1.0, 2.0, and 4.0 %w/w) of PEG 4000, respectively; A₀–D₀ are unloaded SLMs while batches AM₁–DM₁, AM₂–DM₂, and AM₃–DM₃ contain increasing concentrations (1.0, 2.0, and 3.0 %w/w) of miconazole nitrate (MN), respectively.